Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2013

Open Access 01-12-2013 | Research

Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles

Authors: Eleonora Ponterio, Annacarmen Petrizzo, Ilaria Di Bartolo, Franco Maria Buonaguro, Luigi Buonaguro, Franco Maria Ruggeri

Published in: Journal of Translational Medicine | Issue 1/2013

Login to get access

Abstract

Background

Virus-like particles (VLPs) from an Italian GII.4 norovirus strain were used to investigate activation and maturation of circulating antigen presenting cells (APCs) of human origin.

Methods

Peripheral blood mononuclear cells (PBMCs) isolated from five healthy subjects were pulsed ex vivo with VLPs, and stained with a set of monoclonal antibodies (MAbs) for phenotypic analysis by flow cytometry. Cytokine release in cell supernatants was investigated by ELISA.

Results

Norovirus VLPs induced activation and maturation of circulating APCs derived from the five donors, as well as production of IL-6, IFN-γ and TNF-α cytokines.

Conclusions

The present results suggest that VLPs can activate antigen presenting cells for an efficient induction of the adaptive immune response.
Appendix
Available only for authorised users
Literature
1.
Estes MK, Prasad BV, Atmar RL: Noroviruses everywhere: has something changed?. Curr Opin Infect Dis. 2006, 19: 467-474.CrossRefPubMed
2.
Bull RA, Eden JS, Luciani F, McElroy K, Rawlinson WD, White PA: Contribution of intra- and interhost dynamics to norovirus evolution. J Virol. 2012, 86: 3219-3229.PubMedCentralCrossRefPubMed
3.
4.
5.
Donaldson EF, Lindesmith LC, Lobue AD, Baric RS: Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol. 2010, 8: 231-241.CrossRefPubMed
6.
Gray JJ, Kohli E, Ruggeri FM, Vennema H, Sanchez-Fauquier A, Schreier E, Gallimore CI, Iturriza-Gomara M, Giraudon H, Pothier P: European multicenter evaluation of commercial enzyme immunoassays for detecting norovirus antigen in fecal samples. Clin Vaccine Immunol. 2007, 14: 1349-1355.PubMedCentralCrossRefPubMed
7.
Estes MK, Ball JM, Guerrero RA, Opekun AR, Gilger MA, Pacheco SS, Graham DY: Norwalk virus vaccines: challenges and progress. J Infect Dis. 2000, 181 (Suppl 2): S367-373.CrossRefPubMed
8.
Lochridge VP, Jutila KL, Graff JW, Hardy ME: Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions. J Gen Virol. 2005, 86: 2799-2806.CrossRefPubMed
9.
Debbink K, Donaldson EF, Lindesmith LC, Baric RS: Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol. 2012, 86: 1214-1226.PubMedCentralCrossRefPubMed
10.
Tan M, Jiang X: Association of histo-blood group antigens with susceptibility to norovirus infection may be strain-specific rather than genogroup dependent. J Infect Dis. 2008, 198: 940-941. author reply 942–943CrossRefPubMed
11.
12.
13.
Buonaguro L, Tornesello ML, Tagliamonte M, Gallo RC, Wang LX, Kamin-Lewis R, Abdelwahab S, Lewis GK, Buonaguro FM: Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol. 2006, 80: 9134-9143.PubMedCentralCrossRefPubMed
14.
Harper DM: Preliminary HPV vaccine results for women older than 25 years. Lancet. 2009, 373: 1921-1922.CrossRefPubMed
15.
Zhou H, Guo L, Wang M, Qu J, Zhao Z, Wang J, Hung T: Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. Virol J. 2011, 8: 3-PubMedCentralCrossRefPubMed
16.
Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK: Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol. 2001, 75: 9713-9722.PubMedCentralCrossRefPubMed
17.
Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK: Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol. 2003, 108: 241-247.CrossRefPubMed
18.
Souza M, Cheetham SM, Azevedo MS, Costantini V, Saif LJ: Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain). J Virol. 2007, 81: 9183-9192.PubMedCentralCrossRefPubMed
19.
Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM: Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011, 365: 2178-2187.PubMedCentralCrossRefPubMed
20.
21.
22.
Buonaguro L, Monaco A, Arico E, Wang E, Tornesello ML, Lewis GK, Marincola FM, Buonaguro FM: Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics. 2008, 9 (2): S5-PubMedCentralCrossRefPubMed
23.
Arico E, Wang E, Tornesello ML, Tagliamonte M, Lewis GK, Marincola FM, Buonaguro FM, Buonaguro L: Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med. 2005, 3: 45-PubMedCentralCrossRefPubMed
24.
Buonaguro L, Petrizzo A, Tornesello M, Napolitano M, Martorelli D, Castello G, Beneduce G, De Renzo A, Perrella O, Romagnoli L: Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. J Transl Med. 2010, 8: 18-PubMedCentralCrossRefPubMed
25.
Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR, Castro E: Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008, 205: 3119-3131.PubMedCentralCrossRefPubMed
26.
Monaco A, Marincola FM, Sabatino M, Pos Z, Tornesello ML, Stroncek DF, Wang E, Lewis GK, Buonaguro FM, Buonaguro L: Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett. 2009, 583: 3004-3008.CrossRefPubMed
27.
Boccia D, Tozzi AE, Cotter B, Rizzo C, Russo T, Buttinelli G, Caprioli A, Marziano ML, Ruggeri FM: Waterborne outbreak of Norwalk-like virus gastroenteritis at a tourist resort, Italy. Emerg Infect Dis. 2002, 8: 563-568.PubMedCentralCrossRefPubMed
28.
Jiang X, Wang M, Graham DY, Estes MK: Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol. 1992, 66: 6527-6532.PubMedCentralPubMed
29.
Kenney SP, Pudupakam RS, Huang YW, Pierson FW, LeRoith T, Meng XJ: The PSAP motif within the ORF3 protein of an avian strain of the hepatitis E virus is not critical for viral infectivity in vivo but plays a role in virus release. J Virol. 2012, 86: 5637-5646.PubMedCentralCrossRefPubMed
30.
Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E: Protocol 11 study I: Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine. 2008, 26: 686-696.CrossRefPubMed
31.
Kitamoto N, Tanaka T, Natori K, Takeda N, Nakata S, Jiang X, Estes MK: Cross-reactivity among several recombinant calicivirus virus-like particles (VLPs) with monoclonal antibodies obtained from mice immunized orally with one type of VLP. J Clin Microbiol. 2002, 40: 2459-2465.PubMedCentralCrossRefPubMed
32.
Tanaka T, Kitamoto N, Jiang X, Estes MK: High efficiency cross-reactive monoclonal antibody production by oral immunization with recombinant norwalk virus-like particles. Microbiol Immunol. 2006, 50: 883-888.CrossRefPubMed
33.
Tamminen K, Huhti L, Koho T, Lappalainen S, Hytonen VP, Vesikari T, Blazevic V: A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology. 2012, 135: 89-99.PubMedCentralCrossRefPubMed
34.
Lindesmith LC, Debbink K, Swanstrom J, Vinje J, Costantini V, Baric RS, Donaldson EF: Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol. 2012, 86: 873-883.PubMedCentralCrossRefPubMed
35.
Lichtenegger FS, Mueller K, Otte B, Beck B, Hiddemann W, Schendel DJ, Subklewe M: CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS One. 2012, 7: e44266-PubMedCentralCrossRefPubMed
36.
Crow MK: Costimulatory molecules and T-cell-B-cell interactions. Rheum Dis Clin North Am. 2004, 30: 175-191. vii-viiiCrossRefPubMed
37.
38.
Braciale TJ, Morrison LA, Sweetser MT, Sambrook J, Gething MJ, Braciale VL: Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol Rev. 1987, 98: 95-114.CrossRefPubMed
39.
Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS: Cellular and humoral immunity following Snow Mountain virus challenge. J Virol. 2005, 79: 2900-2909.PubMedCentralCrossRefPubMed
40.
Souza M, Costantini V, Azevedo MS, Saif LJ: A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine. 2007, 25: 8448-8459.PubMedCentralCrossRefPubMed
41.
Nicollier-Jamot B, Pico V, Pothier P, Kohli E: Molecular cloning, expression, self-assembly, antigenicity, and seroepidemiology of a genogroup II norovirus isolated in France. J Clin Microbiol. 2003, 41: 3901-3904.PubMedCentralCrossRefPubMed
42.
Periwal SB, Kourie KR, Ramachandaran N, Blakeney SJ, DeBruin S, Zhu D, Zamb TJ, Smith L, Udem S, Eldridge JH: A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine. Vaccine. 2003, 21: 376-385.CrossRefPubMed
Metadata
Title
Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles
Authors
Eleonora Ponterio
Annacarmen Petrizzo
Ilaria Di Bartolo
Franco Maria Buonaguro
Luigi Buonaguro
Franco Maria Ruggeri
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-11-127

Other articles of this Issue 1/2013

Journal of Translational Medicine 1/2013 Go to the issue

Research

Clear cell renal cell carcinoma associated microRNA expression signatures identified by an integrated bioinformatics analysis

Research

Identifying translational science within the triangle of biomedicine

Research

Circulating microRNA: a novel potential biomarker for early diagnosis of Intracranial Aneurysm Rupture a case control study

Research

Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel

Research

Down-regulation of miR-138 promotes colorectal cancer metastasis via directly targeting TWIST2

Research

Innate immunity activation involved in unprotected porcine auto-transplant kidneys preserved by naked caspase-3 siRNA
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits